PFA
AZN icon

Pure Financial Advisors’s AstraZeneca AZN Stock Holding History

Pure Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Buy
2,475
+88
+4% +$16.6K 0.01% 390
2026
Q1 		$471K Sell
2,387
-566
-19% -$109K 0.01% 349
2025
Q4 		$543K Buy
2,953
+854
+41% +$150K 0.01% 297
2025
Q3 		$322K Buy
2,099
+489
+30% +$74K 0.01% 383
2025
Q2 		$225K Buy
+1,610
New +$226K ﹤0.01% 436

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Pure Financial Advisors's AZN Position: Q2 2026 in Review

Pure Financial Advisors increased its AstraZeneca (AZN) stake by 3.7% in Q2 2026, buying an estimated $16.6K and bringing the position to 2,475 shares worth $469K. The position accounts for 0.01% of the portfolio, ranked #390.

Pure Financial Advisors first reported a position in AZN in Q2 2025 and has held it in 5 quarters since. The position peaked at $543K in Q4 2025. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Pure Financial Advisors held 2,475 shares of AstraZeneca worth $469K as of Q2 2026.
  • Pure Financial Advisors bought 88 AstraZeneca shares in Q2 2026, an estimated $16.6K.
  • AstraZeneca made up 0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #390 holding.
  • Pure Financial Advisors first reported a position in AstraZeneca in Q2 2025 and has held it in 5 quarters since.
  • Pure Financial Advisors's AstraZeneca position peaked at $543K in Q4 2025.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.